These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 9384478

  • 21. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
    Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ.
    Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
    [Abstract] [Full Text] [Related]

  • 22. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [Abstract] [Full Text] [Related]

  • 23. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [Abstract] [Full Text] [Related]

  • 24. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen.
    Subirà M, Sureda A, Martino R, García J, Altés A, Canals C, Domingo-Albós A, Brunet S, Sierra J.
    Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724
    [Abstract] [Full Text] [Related]

  • 25. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
    Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J, Moskowitz CH.
    Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
    [Abstract] [Full Text] [Related]

  • 26. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM.
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [Abstract] [Full Text] [Related]

  • 27. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 28. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
    Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ, Klingemann HG, Connors JM, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Fairey RN, O'Reilly SE, Phillips GL.
    Bone Marrow Transplant; 1999 Jun; 23(11):1131-8. PubMed ID: 10382952
    [Abstract] [Full Text] [Related]

  • 29. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
    Torjman L, Ladeb S, Lakhal A, Ben Othman T, Abdelkefi A, Ben Abdeladhim A.
    Tunis Med; 2007 Jan; 85(1):35-8. PubMed ID: 17424707
    [Abstract] [Full Text] [Related]

  • 30. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
    Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR, McCurley TL, Wolff SN.
    Bone Marrow Transplant; 2000 Feb; 25(3):257-62. PubMed ID: 10673696
    [Abstract] [Full Text] [Related]

  • 31. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [Abstract] [Full Text] [Related]

  • 32. Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors.
    Mandanas RA, Saez RA, Epstein RB, Confer DL, Selby GB.
    Bone Marrow Transplant; 1998 Mar; 21(6):569-76. PubMed ID: 9543060
    [Abstract] [Full Text] [Related]

  • 33. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [Abstract] [Full Text] [Related]

  • 34. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
    Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A.
    Cancer; 2003 Jun 01; 97(11):2748-59. PubMed ID: 12767087
    [Abstract] [Full Text] [Related]

  • 35. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct 01; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 36. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    Ganguly S, Divine CL, Deauna-Limayo D, Bodensteiner DC, Cook JD, Lewis JN, Skikne BS.
    Ann Hematol; 2005 Aug 01; 84(8):526-31. PubMed ID: 15915350
    [Abstract] [Full Text] [Related]

  • 37. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):208-18. PubMed ID: 15093918
    [Abstract] [Full Text] [Related]

  • 38. Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin's disease: equivalent survival outcome in a single-centre matched-pair analysis.
    Perry AR, Peniket AJ, Watts MJ, Leverett D, Goldstone AH, Linch DC.
    Br J Haematol; 1999 Apr 01; 105(1):280-7. PubMed ID: 10233395
    [Abstract] [Full Text] [Related]

  • 39. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP, Stiff PJ, Toor AA, Parthasarathy M.
    Biol Blood Marrow Transplant; 2003 Mar 01; 9(3):177-82. PubMed ID: 12652468
    [Abstract] [Full Text] [Related]

  • 40. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices.
    Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP, Agarwal R.
    J Clin Oncol; 2004 Nov 15; 22(22):4532-40. PubMed ID: 15542804
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.